Log In
Sunday 20th May 2018

Lung cancer drug banned

14th November 2006

21092006_smoker1.jpgThe NHS has banned a lung cancer drug, despite claims it could lengthen thousands of lives.

The National Institute for Health and Clinical Excellence has not recommended the use of Erlotinib, trading under the name Tarceva, to treat non-small cell lung cancer.

The drug is currently available for patients in Scotland whose disease has spread and costs £6,800 for a typical course of treatment. It is used as a standard treatment in some countries to prolong life and relieve symptoms.

There are 37,100 new cases of lung cancer in Britain each year and 33,000 deaths. Non-small cell lung cancer accounts for 80 per cent of the total.

Cancer Research UK said it was disappointed by the findings. The charity is funding research into the drug.

Share this page



Tuesday 14th November 2006 @ 19:36

Is Tarceva only banned in the UK or is it in the US also? I have lung cancer and have taken chemo treatments but not Tarceva. However, I was under the impression that I could take Traceva if the cancer should return. What a shame for this drug to be banned as I have a close friend who is in stage IV lung cancer and doing well (over a year) on Tarceva.


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018